{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:23:02Z","timestamp":1786987382842,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.coph.2020.10.015","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T11:59:52Z","timestamp":1606478392000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?"],"prefix":"10.1016","volume":"55","author":[{"given":"Ferdinando","family":"D\u2019Amico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.10.015_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primer"},{"key":"10.1016\/j.coph.2020.10.015_bib0010","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.015_bib0015","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.015_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2020.10.015_bib0025","series-title":"Remicade","author":"Anonymous","year":"2018"},{"key":"10.1016\/j.coph.2020.10.015_bib0030","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cgh.2020.01.017","article-title":"Positioning therapies in ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2020.10.015_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_bib0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2020.10.015_bib0045","first-page":"1","article-title":"Emerging therapies for the treatment of ulcerative colitis","author":"Pugliese","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.coph.2020.10.015_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104886","article-title":"What\u2019s new in IBD therapy: an \u201comics network\u201d approach","volume":"159","author":"Fiocchi","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coph.2020.10.015_bib0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2016.10.018","article-title":"Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0060","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.015_bib0065","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.015_bib0070","series-title":"Skyrizi","author":"Buckingham","year":"2019"},{"key":"10.1016\/j.coph.2020.10.015_bib0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2020.10.015_bib0080","doi-asserted-by":"crossref","first-page":"S024","DOI":"10.1093\/ecco-jcc\/jjz203.026","article-title":"OP27 long-term safety and efficacy of risankizumab treatment in patients with Crohn\u2019s disease: final results from the phase 2 open-label extension study","volume":"14","author":"Ferrante","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_sbref0085","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0090","doi-asserted-by":"crossref","first-page":"S-1187","DOI":"10.1016\/S0016-5085(20)33636-2","article-title":"Tu1849 histologic remission and mucosal healing in a phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis","volume":"158","author":"Pai","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1016\/j.coph.2020.10.015_bib0095","doi-asserted-by":"crossref","first-page":"S026","DOI":"10.1093\/ecco-jcc\/jjy222.035","article-title":"OP38 maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis","volume":"13","author":"D\u2019Haens","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_bib0100","doi-asserted-by":"crossref","first-page":"S-216","DOI":"10.1016\/S0016-5085(19)37335-4","article-title":"1003 \u2014 efficacy and safety of mirikizumab (LY3074828) in a phase 2 study of patients with Crohn\u2019s disease","volume":"156","author":"Sands","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14712598.2020.1697227","article-title":"Anti-interleukin-23 agents for the treatment of ulcerative colitis","volume":"20","author":"Han\u017eel","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coph.2020.10.015_bib0115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bpg.2018.05.015","article-title":"JAK inhibitors: novel developments in management of ulcerative colitis","volume":"32\u201333","author":"Fiorino","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.coph.2020.10.015_bib0120","series-title":"Xeljanz","author":"Czarska-Thorley","year":"2019"},{"key":"10.1016\/j.coph.2020.10.015_bib0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.015_bib0130","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"Supplement_1","key":"10.1016\/j.coph.2020.10.015_sbref0135","doi-asserted-by":"crossref","first-page":"S057","DOI":"10.1093\/ecco-jcc\/jjy222.084","article-title":"DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn\u2019s disease: data from the CELEST study","volume":"13","author":"Peyrin-Biroulet","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_bib0140","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0145","article-title":"Upadacitinib for Crohn\u2019s disease and ulcerative colitis treatment: hitting the selective JAKpot","author":"Parigi","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0150","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine program","volume":"14","author":"Sandborn","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_bib0155","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/ecco-jcc\/jjaa074","article-title":"JAK or GUT selectivity: tipping the balance for efficacy and safety in ulcerative colitis","volume":"14","author":"D\u2019Amico","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_bib0160","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","article-title":"JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?","volume":"68","author":"Danese","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.015_bib0165","article-title":"Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis","author":"De Vries","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_bib0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1381612825666190307165703","article-title":"Anti-adhesion molecules in IBD: does gut selectivity really make the difference?","volume":"25","author":"D\u2019Amico","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.coph.2020.10.015_bib0175","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2217\/imt-2018-0209","article-title":"Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing","volume":"11","author":"D\u2019Amico","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.coph.2020.10.015_bib0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14712598.2020.1717465","article-title":"Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?","volume":"20","author":"D\u2019Amico","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coph.2020.10.015_bib0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.015_bib0190","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s12325-020-01366-2","article-title":"Etrolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease: an overview of the phase 3 clinical program","volume":"37","author":"Sandborn","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.coph.2020.10.015_sbref0195","series-title":"Roche Provides Update on Phase III Studies of Etrolizumab in People with Moderately to Severely Active Ulcerative Colitis","author":"Anon","year":"2020"},{"key":"10.1016\/j.coph.2020.10.015_bib0200","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.gastro.2018.11.035","article-title":"Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis","volume":"156","author":"Sandborn","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0205","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of \u03b14 integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.015_bib0215","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2016-313457","article-title":"Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn\u2019s disease: report of the OPERA study","volume":"67","author":"Sandborn","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.coph.2020.10.015_bib0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coph.2020.10.015_bib0225","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2020.10.015_bib0230","first-page":"S3","article-title":"Ozanimod, an oral S1P receptor modulator, is effective and well-tolerated in the long-term treatment of moderate to severe ulcerative colitis: P-012","volume":"113","author":"Brian","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2020.10.015_sbref0235","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2020.10.015_bib0240","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2020.10.015_bib0245","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/14712598.2020.1695775","article-title":"Rationale for IL-36 receptor antibodies in ulcerative colitis","volume":"20","author":"Neufert","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coph.2020.10.015_bib0250","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2020.10.015_bib0255","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2020.10.015_bib0260","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ecco-jcc\/jjz003","article-title":"The evolution of health care utilisation and costs for inflammatory bowel disease over ten years","volume":"13","author":"Pillai","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2020.10.015_bib0265","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4060648","article-title":"Treatment adherence in inflammatory bowel disease patients from argentina: a multicenter study","volume":"2020","author":"Lasa","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.coph.2020.10.015_bib0270","first-page":"1","article-title":"Patient\u2019s profiling for therapeutic management of inflammatory bowel disease: a tailored approach","author":"D\u2019Amico","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2020.10.015_sbref0275","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2020.10.015_bib0280","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"key":"10.1016\/j.coph.2020.10.015_bib0285","first-page":"A53","article-title":"OTU-003 etrolizumab as induction therapy in moderate to severe Crohn\u2019s disease: results from bergamot cohort 1","volume":"67","author":"Selinger","year":"2018","journal-title":"Gut"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:55:02Z","timestamp":1761461702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489220301181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":57,"alternative-id":["S1471489220301181"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.015","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}